ATE262920T1 - Kontinuierliche, niedrigdosierte zytokine- infusionstherapie - Google Patents
Kontinuierliche, niedrigdosierte zytokine- infusionstherapieInfo
- Publication number
- ATE262920T1 ATE262920T1 AT96936938T AT96936938T ATE262920T1 AT E262920 T1 ATE262920 T1 AT E262920T1 AT 96936938 T AT96936938 T AT 96936938T AT 96936938 T AT96936938 T AT 96936938T AT E262920 T1 ATE262920 T1 AT E262920T1
- Authority
- AT
- Austria
- Prior art keywords
- low dose
- cytokine
- continuous
- infusion therapy
- dose cytokine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US613095P | 1995-11-02 | 1995-11-02 | |
PCT/US1996/017085 WO1997016204A1 (en) | 1995-11-02 | 1996-10-31 | Continuous low-dose cytokine infusion therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE262920T1 true ATE262920T1 (de) | 2004-04-15 |
Family
ID=21719457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96936938T ATE262920T1 (de) | 1995-11-02 | 1996-10-31 | Kontinuierliche, niedrigdosierte zytokine- infusionstherapie |
Country Status (12)
Country | Link |
---|---|
US (1) | US6461605B1 (de) |
EP (1) | EP0858343B1 (de) |
JP (2) | JP2000507917A (de) |
AT (1) | ATE262920T1 (de) |
AU (1) | AU7473096A (de) |
CA (2) | CA2236591C (de) |
DE (1) | DE69632062T2 (de) |
DK (1) | DK0858343T3 (de) |
ES (1) | ES2214551T3 (de) |
MX (1) | MX9803448A (de) |
PT (1) | PT858343E (de) |
WO (1) | WO1997016204A1 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
EP0858343B1 (de) | 1995-11-02 | 2004-03-31 | Schering Corporation | Kontinuierliche, niedrigdosierte zytokine-infusionstherapie |
BR9812267B1 (pt) * | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
CN1191863C (zh) * | 1998-03-26 | 2005-03-09 | 先灵公司 | 用于保护PEG-α干扰素缀合物的制剂 |
CN1230198C (zh) * | 1998-05-15 | 2005-12-07 | 先灵公司 | 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法 |
EP1087778B1 (de) * | 1998-06-08 | 2005-10-26 | F. Hoffmann-La Roche Ag | Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c |
AU6037499A (en) * | 1998-09-14 | 2000-04-03 | Vertex Pharmaceuticals Incorporated | Methods of treating viral disease |
US6685931B1 (en) | 1998-12-22 | 2004-02-03 | Schering Corporation | Treatment of hepatitis C virus infections with interleukin-10 |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
DE60018273T2 (de) * | 1999-05-04 | 2005-08-18 | Schering Corp. | Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv-therapie |
CA2405912A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2002010743A1 (en) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
CN1516599A (zh) * | 2000-10-18 | 2004-07-28 | ���鹫˾ | 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法 |
US6720000B2 (en) * | 2001-03-19 | 2004-04-13 | Three Rivers Pharmaceutical, Llc | Process for producing wet ribavirin pellets |
EP1443911A1 (de) * | 2001-11-02 | 2004-08-11 | Geneva Pharmaceuticals, Inc. | Verfahren zur herstellung von schnell auflösenden, hoch beladenen ribavirin-zusammensetzungen |
WO2003049760A1 (en) * | 2001-12-07 | 2003-06-19 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
AU2003214044B8 (en) * | 2002-01-17 | 2008-11-13 | Polymun Scientific Immunbiologische Forschung Gmbh | Anti-idiotypic antibody inducing HIV-1 neutralizing antibodies |
US7611700B2 (en) | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
US7538094B2 (en) * | 2002-09-19 | 2009-05-26 | Three Rivers Pharmacueticals, Llc | Composition containing ribavirin and use thereof |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20070077225A1 (en) * | 2003-02-28 | 2007-04-05 | Blatt Lawrence M | Continuous delivery methods for treating hepatitis virus infection |
JP4629964B2 (ja) * | 2003-09-12 | 2011-02-09 | 株式会社林原生物化学研究所 | ウシの消化器疾患治療剤 |
WO2005039622A2 (en) * | 2003-10-21 | 2005-05-06 | Medtronic Minimed, Inc. | Modulation of socs expression in the therapeutic regimens |
ES2294589T3 (es) | 2004-04-29 | 2008-04-01 | F. Hoffmann-La Roche Ag | Variacion de la secuencia nucleosida de ns5a como marcador. |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US7714114B2 (en) | 2005-02-16 | 2010-05-11 | Nektar Therapeutics | Conjugates of an EPO moiety and a polymer |
ES2302402B1 (es) | 2005-06-16 | 2009-05-08 | Proyecto De Biomedicina Cima, S.L. | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
US20070231301A1 (en) * | 2006-03-31 | 2007-10-04 | Warren Stephen L | Parenteral low dose type 1 interferons for bladder cancer |
PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
MX2009011123A (es) | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Formulaciones de suspensiones de peptidos insulinotropicos y sus usos. |
KR20100056479A (ko) | 2007-07-25 | 2010-05-27 | 바이오렉스 쎄라퓨틱스, 인코포레이티드 | 제어 방출 인터페론 약물 제품 및 이를 사용한 hcv 감염의 치료 |
US20110270212A1 (en) * | 2007-10-05 | 2011-11-03 | Medtronic, Inc. | Pharmacokinetic control for optimized interferon delivery |
EP2240155B1 (de) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe |
EA022952B1 (ru) * | 2008-07-23 | 2016-03-31 | Тамара Александровна ВИТКАЛОВА | Способ лечения вирусных гепатитов b и c |
CN102159245B (zh) * | 2008-09-17 | 2013-07-24 | 贝林格尔.英格海姆国际有限公司 | Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合 |
US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
NZ598686A (en) | 2009-09-28 | 2014-05-30 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
BR112012010110A2 (pt) | 2009-10-30 | 2019-09-24 | Boehringer Ingelheim Int | regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
EP3565580B1 (de) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
US4140761A (en) | 1977-04-11 | 1979-02-20 | The United States Of America As Represented By The Department Of Health, Education & Welfare | Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4774091A (en) | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
IL76591A0 (en) | 1984-10-05 | 1986-02-28 | Bioferon Biochem Substanz | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
NZ217844A (en) | 1985-10-11 | 1989-10-27 | Sumitomo Pharma | A sustained release pharmaceutical composition containing silicone elastomer and an albumin |
NZ219027A (en) * | 1986-01-24 | 1989-09-27 | Genentech Inc | Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
ZA878295B (en) | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
AU3945393A (en) * | 1992-04-14 | 1993-11-18 | Schering Corporation | Treatment of hepatitis with GM-CSF |
DE69317428T2 (de) * | 1992-08-19 | 1998-07-02 | Schering Corp | Methode zur inhibition von hiv-replikation mittels il-4 |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
MX9307733A (es) * | 1992-12-23 | 1994-06-30 | Schering Corp | Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo. |
CN1072961C (zh) | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
WO1995013090A1 (en) | 1993-11-10 | 1995-05-18 | Enzon, Inc. | Improved interferon polymer conjugates |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
EP0858343B1 (de) | 1995-11-02 | 2004-03-31 | Schering Corporation | Kontinuierliche, niedrigdosierte zytokine-infusionstherapie |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5767097A (en) | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
US5849800A (en) | 1997-03-28 | 1998-12-15 | The Penn State Research Foundation | Use of amantadine for treatment of Hepatitis C |
-
1996
- 1996-10-31 EP EP96936938A patent/EP0858343B1/de not_active Revoked
- 1996-10-31 AT AT96936938T patent/ATE262920T1/de active
- 1996-10-31 WO PCT/US1996/017085 patent/WO1997016204A1/en active IP Right Grant
- 1996-10-31 CA CA2236591A patent/CA2236591C/en not_active Expired - Lifetime
- 1996-10-31 CA CA002329474A patent/CA2329474C/en not_active Expired - Lifetime
- 1996-10-31 DK DK96936938T patent/DK0858343T3/da active
- 1996-10-31 ES ES96936938T patent/ES2214551T3/es not_active Expired - Lifetime
- 1996-10-31 DE DE1996632062 patent/DE69632062T2/de not_active Expired - Lifetime
- 1996-10-31 AU AU74730/96A patent/AU7473096A/en not_active Abandoned
- 1996-10-31 JP JP9517418A patent/JP2000507917A/ja not_active Withdrawn
- 1996-10-31 PT PT96936938T patent/PT858343E/pt unknown
-
1998
- 1998-04-30 MX MX9803448A patent/MX9803448A/es unknown
-
2002
- 2002-03-22 US US10/104,287 patent/US6461605B1/en not_active Expired - Lifetime
-
2003
- 2003-01-27 JP JP2003017565A patent/JP2003246750A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0858343B1 (de) | 2004-03-31 |
AU7473096A (en) | 1997-05-22 |
DE69632062T2 (de) | 2004-11-18 |
MX9803448A (es) | 1998-09-30 |
CA2329474C (en) | 2002-02-26 |
WO1997016204A1 (en) | 1997-05-09 |
ES2214551T3 (es) | 2004-09-16 |
DK0858343T3 (da) | 2004-05-10 |
CA2236591A1 (en) | 1997-05-09 |
PT858343E (pt) | 2004-07-30 |
US6461605B1 (en) | 2002-10-08 |
EP0858343A1 (de) | 1998-08-19 |
DE69632062D1 (de) | 2004-05-06 |
JP2003246750A (ja) | 2003-09-02 |
JP2000507917A (ja) | 2000-06-27 |
CA2236591C (en) | 2012-01-03 |
CA2329474A1 (en) | 1997-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE262920T1 (de) | Kontinuierliche, niedrigdosierte zytokine- infusionstherapie | |
RO115700B1 (ro) | Metodă de tratament cu interferon | |
NZ309217A (en) | Ribavirin and interferon alpha for the treatment of hepatitis C | |
DK1169059T3 (da) | Docetaxel i kombination med rhuMAb HER2 til behandling af cancere | |
NO952469L (no) | Terapautisk kombinasjon som inneholder interferon | |
IL134345A0 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
DE60237721D1 (de) | Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen | |
WO2005039622A3 (en) | Modulation of socs expression in the therapeutic regimens | |
FI954127A0 (fi) | Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa | |
KR900701311A (ko) | 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 | |
WO1999013894A3 (en) | Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c | |
DE60125377D1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin | |
DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon | |
UA49320A (uk) | Спосіб лікування пневмоцистозу у хворих на хронічний бронхіт |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0858343 Country of ref document: EP |